Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects

NCT03626714 is registered in ClinicalTrials.gov with Auritec Pharmaceuticals as lead sponsor.

NCT NCT03626714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03626714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects
Lead sponsor
Auritec Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
October 16, 2018
Completion date
January 5, 2019
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

organ transplant rejection, psoriasis